Skip to main content
Equibles
SMMT logo

SMMT · Summit Therapeutics Inc. · Earnings Call Transcripts & Audio

Track SMMT — free

Use SMMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.91 +0.52 (+3.17%) At close · Sep 30
Russell 1000 member Rebalance outlook locked
Going-concern doubt — flagged Jul 23, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Jul 23, 2026
Market Cap
$12.45B
Shares
797.75M
Volume · Sep 30 13.06M Avg daily vol (3M) 5.57M

Summit Therapeutics Inc. Earnings Call Transcripts

Quarterly earnings calls for Summit Therapeutics Inc. (SMMT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼100% $ −$19.23M '22 Q4 23-03-09 ▼100% $ −$542.38M '23 Q1 23-05-11 ▼100% $ −$14.72M '23 Q2 23-08-09 ▼100% $ −$21.27M '23 Q3 23-11-07 · $ −$36.57M '23 Q4 24-02-20 LATEST · $ −$56.25M '24 Q3 24-10-30
Earnings call
FY26 · Q2
2026-07-23
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Confident tone HARMONY trial updated OS analysis HARMONY 3 and HARMONY 6 NSCLC trials Commercial uptake in China
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Summit Therapeutics Inc. (SMMT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-06-01
Summit Therapeutics Inc. (SMMT) Q1 2026 Earnings Call
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
Confident tone Ivonescimab data readouts and approvals FDA BLA review and HARMONi regulatory path HARMONi-3 trial progress and interim analysis
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-20
Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript
Confident tone BLA submission for ivonescimab HARMONi-6 Phase III data in squamous NSCLC HARMONi-3 independent histologies and filing strategy
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript
Confident tone HARMONi global Phase III trial readout Ivonescimab clinical progress and regulatory milestones Partnership with Akeso
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript
Confident tone Harmony 3 amendment and patient population expansion Pfizer ADC collaboration Harmony 7 monotherapy vs pembrolizumab trial
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
Confident tone HARMONi-3 amendment to include non-squamous NSCLC HARMONi EGFR-mutant Phase 3 enrollment and timeline HARMONi-2 ivonescimab vs pembro data
Revenue
$
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
Confident tone Ivonescimab clinical development and mechanism HARMONi and HARMONi-3 registrational trials Akeso partnership and HARMONi-A data
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript
Confident tone Ivonescimab lead asset progress Unmet need in lung cancer Akeso partnership and global trials
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Summit Therapeutics Inc. (SMMT) Q3 2023 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Summit Therapeutics Inc. (SMMT) Q2 2023 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Summit Therapeutics Inc. (SMMT) Q1 2023 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-1.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–15 of 15 earnings calls
Key facts CIK 1599298 CUSIP 86627T108 13F (30d) 6 filings 6 filers Visit website Investor relations